← Back to catalogue
Published

mecamylamine

vr.tr.mecamylamine · thing-q3332124

Enable an agent to identify mecamylamine, assess the suitability of a supplied material or reported exposure, and determine which research or handling actions its evidence supports.

Thing Registry Physical world and living systems PHY.OBJ

Bundle → Layer → Finding → Questions Filled

6 bundles · 11 layers · 17 findings · 32 questions

Molecular identity Establish what the mecamylamine name denotes in each record.

Structure and identifiers

Connect the registry entry to a verified molecular reference.

Reference identity match

Require agreement between the declared structure and identifiers before accepting a mecamylamine match.

  1. Which authoritative structure and identifiers define mecamylamine for this record? definition
  2. Which inspected reference establishes that these identifiers denote the same chemical entity? provenance

Salt and stereochemistry

Preserve distinctions obscured by the unqualified substance name.

Form-specific equivalence

Treat salt form and stereochemical composition as explicit qualifications of a mecamylamine material.

  1. Does this record describe the free base, hydrochloride or an incompletely specified preparation? boundary
  2. What evidence establishes its stereochemical composition? provenance
  3. Does the proposed comparison require identical stereochemistry or only a shared active moiety? boundary
Material and preparation Determine whether the actual material supports reliable mecamylamine measurements.

Lot characterization

Assess evidence for identity, content and relevant impurities.

Verified mecamylamine content

Distinguish identity confirmation, quantitative assay and impurity profiling when judging a supplied lot.

  1. Which analytical results confirm mecamylamine identity in this lot? provenance
  2. What content was measured, and is it expressed on a salt, free-base, dry or as-is basis? measurement
  3. Which impurity or stereochemical limits determine suitability for the intended use? action

Solution and storage state

Qualify concentration and usability after preparation or storage.

Usable preparation

Evaluate the actual mecamylamine form and matrix rather than transferring tablet or supplier storage claims to every preparation.

  1. What solvent, pH, chemical form and assay correction underpin the stated concentration? measurement
  2. Which stability evidence applies to this container, matrix and storage history? provenance
  3. What evidence requires reanalysis, quarantine or rejection before use? action
Nicotinic blockade Represent mecamylamine's documented nicotinic antagonist role and the evidence needed to interpret a particular response. [NLM MeSH](https://www.ncbi.nlm.nih.gov/mesh/68008464)

Receptor assay context

Attach inhibition measurements to the tested receptor system.

Conditional potency

Record potency as an assay-dependent observation, preserving receptor composition and stimulation conditions.

  1. Which species, receptor subunits and expression system were tested? definition
  2. What inhibition was measured at which concentrations, agonist conditions and exposure times? measurement

Effect attribution

Determine how strongly a response supports a nicotinic mechanism.

Mechanistic inference limits

Require controls before attributing an observed change exclusively to a particular nicotinic receptor population.

  1. Which controls distinguish nicotinic blockade from nonspecific toxicity or other explanations? provenance
  2. Does the evidence support subtype attribution, broader nicotinic involvement or only an observed mecamylamine response? boundary
Exposure and distribution Connect administered or applied material to the exposure relevant to an observed effect.

Site of exposure

Separate route and applied amount from demonstrated exposure in a target compartment.

Central and peripheral interpretation

Mecamylamine crosses the blood-brain barrier; an observed response therefore requires evidence to localize its origin. [NLM MeSH](https://www.ncbi.nlm.nih.gov/mesh/68008464)

  1. What route, formulation and sampling times define the exposure? measurement
  2. What measurements or controls distinguish central from peripheral contributions? provenance

Elimination context

Capture conditions that affect persistence and comparisons across exposures.

Renal and pH dependence

The hydrochloride label reports unchanged urinary excretion and reduced elimination with urine alkalinization. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b79ef78-f4da-49a6-9f36-89b0da19d39b)

  1. What renal-function and urinary-pH information accompanies the exposure evidence? measurement
  2. Which measured time-course data justify the assumed persistence or washout interval? provenance
Use and safety boundaries Connect a proposed use to applicable evidence and mecamylamine-specific hazards.

Use evidence

Distinguish documented medicinal indications from experimental purposes.

Purpose-specific authorization

Attach medicinal claims to a specific product label and jurisdiction; attach research claims to the studied system.

  1. Is the proposed use analytical, preclinical, clinical research or treatment? boundary
  2. Which current label, protocol or institutional authorization applies to that use? provenance
  3. Does the material's documented grade support the proposed use? action

Hazard-triggered review

Identify evidence requiring a pause or specialist assessment.

Autonomic and central hazards

The hydrochloride label identifies postural hypotension, ileus, urinary retention and central nervous system adverse effects. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b79ef78-f4da-49a6-9f36-89b0da19d39b)

  1. Which applicable contraindications, interacting exposures or observed adverse effects require specialist review? action
  2. Which handling controls and disposal requirements are specified by the safety data sheet for this exact material? provenance
  3. Who is authorized to decide whether a flagged clinical or experimental exposure may proceed? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.

Reported evidence

Findings from the breadth pass, kept separate from the structural claims.

Check these first

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these check these first hold for the sense of mecamylamine this model covers, and on what evidence? provenance

Kinds and varieties

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these kinds and varieties hold for the sense of mecamylamine this model covers, and on what evidence? provenance

Identifiers and schemes

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these identifiers and schemes hold for the sense of mecamylamine this model covers, and on what evidence? provenance

Real-world use

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these real-world use hold for the sense of mecamylamine this model covers, and on what evidence? provenance

Typical measurements

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these typical measurements hold for the sense of mecamylamine this model covers, and on what evidence? provenance

Failure modes and hazards

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these failure modes and hazards hold for the sense of mecamylamine this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Recalled without web access and unsourced; every item is a lead to verify.

  1. Which of these neighbouring kinds and how to tell them apart hold for the sense of mecamylamine this model covers, and on what evidence? provenance

Classifiers Filled

Family
Thing Registry
Category
Physical world and living systems
Entry kind
thing
Plane
PHY
Domain
PHY.OBJ
Other names and narrower kinds
dexmecamylamine

What it is Filled

Mecamylamine is a synthetic, centrally penetrant, noncompetitive antagonist of neuronal nicotinic acetylcholine receptors that blocks autonomic ganglionic transmission and has been used as an antihypertensive drug.

In scope

  • Mecamylamine identity, structural identifiers and stereochemical specification
  • Relationships between the free base, hydrochloride salt and preparations containing them
  • Material identity, assay, concentration and fitness for a stated use
  • Nicotinic antagonism and interpretation of experimental effects
  • Exposure dependencies and substance-specific safety constraints

Out of scope

  • Finished medicine brands, packaging and commercial availability
  • Individual patient diagnoses, prescriptions and treatment decisions
  • Complete experimental protocols and clinical trial operations
  • Nicotinic receptor biology beyond relationships needed to interpret mecamylamine effects
  • Manufacturing facilities and general chemical inventory management

Why it exists Filled

Enable an agent to identify mecamylamine, assess the suitability of a supplied material or reported exposure, and determine which research or handling actions its evidence supports.

Distinguishing features Filled

  • Require a structure-level match to the specified mecamylamine reference; a similar name or shared ganglion-blocking activity is insufficient.
  • Separate active-moiety identity from salt identity: the cited label distinguishes mecamylamine UNII 6EE945D3OK from its hydrochloride UNII 4956DJR58O. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b79ef78-f4da-49a6-9f36-89b0da19d39b)
  • Classify its documented activity as nicotinic antagonism and ganglionic blockade; a generic 'anticholinergic' description is insufficient. [NLM MeSH](https://www.ncbi.nlm.nih.gov/mesh/68008464)
  • Account for documented blood-brain barrier penetration when distinguishing it from a purely peripheral experimental blocker. [NLM MeSH](https://www.ncbi.nlm.nih.gov/mesh/68008464)
  • Check stereochemical documentation before treating racemic, stereochemically unspecified and enantiomer-specific records as interchangeable.

What robots and AI may and may not do Filled

Must not

  • Recommend, dose or adjust mecamylamine for a particular person.
  • Promote it for unapproved uses such as quitting smoking or mood without medical supervision.
  • Downplay risks of very low blood pressure and bowel or bladder problems.
  • Help anyone obtain it without a prescription.

Only with a human decision

  • Any prescribing or clinical trial decision involving the drug.

May

  • Describe mecamylamine, its history as an antihypertensive and its research uses from official sources.
  • Report prescribing information and warnings from regulatory labelling.

Moral aspects Filled

  • Drugs acting on the nervous system can cause serious side effects that need careful use.

Who is affected

  • Patients
  • Research participants
  • Prescribers

Owners Filled

Steward

The prescribing clinician answers for each use; medicines regulators authorize the product.

Master systems

  • National medicines registers

Links to other meta-models Filled

parent

  • Q108196373 - registry parent class
  • Q12140 - registry parent class

What else AI and robots need to interact with it Filled

Identity and identifiers required Filled

  • Vercy registry: vr.tr.mecamylamine
  • Wikidata: Q3332124 (https://www.wikidata.org/wiki/Q3332124)

Direct properties required Filled

  • Supplied chemical form: free base | hydrochloride | other documented form | unspecified
  • Stereochemical specification: racemate | specified stereoisomer | characterized mixture | unspecified
  • Identity evidence: Links to structure reference, reference standard and analytical report
  • Mecamylamine content: % w/w or mg/g; state salt/free-base and dry/as-is basis
  • Preparation concentration: mol/L or mg/mL with chemical form, solvent and preparation date
  • Functional inhibition: % inhibition or IC50 in mol/L, with receptor composition and assay conditions
  • Exposure context: Links to route, biological system, sampling time and measured exposure
  • Material disposition: unverified | suitable for specified use | quarantined | rejected

Recognition required Filled

  • A container label naming mecamylamine provides a provisional identification that should agree with the accompanying analytical documentation.
  • Label details specifying the salt form and stereoisomer composition distinguish supplied materials that the general substance name leaves ambiguous.
  • Color and physical appearance cannot reliably distinguish mecamylamine from other chemicals or distinguish its stereoisomers.

Capabilities and actions required Filled

  • Resolve a supplier or literature record to mecamylamine while preserving chemical-form distinctions.
  • Normalize reported quantities after verifying salt, assay and concentration bases.
  • Compare inhibition results only when receptor and assay conditions are sufficiently aligned.
  • Assess whether a supplied lot supports a specified analytical or research use.
  • Flag exposure or safety conditions requiring specialist review.
  • Link a containing medicinal product or experiment to this substance without merging their identities.

Hazards and failure modes required Filled

  • Can cause fainting from low blood pressure, constipation and urinary retention.
  • Sudden withdrawal can cause a rebound in blood pressure.

Standards and interfaces required Filled

  • The Anatomical Therapeutic Chemical classification, maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology, classifies mecamylamine as C02BB01 among ganglion-blocking antihypertensives.
  • The Globally Harmonized System of Classification and Labelling of Chemicals, published by the United Nations Economic Commission for Europe, provides a framework for hazard communication for mecamylamine chemical supplies.

Context of use required Filled

  • Mecamylamine is encountered in pharmacological research on neuronal nicotinic receptors and autonomic ganglionic transmission.
  • It also appears in records of antihypertensive treatment and assessments of supplied chemical or pharmaceutical material.
  • Interpreting a sample requires distinguishing its stereoisomer composition and chemical form from the general substance name.

Sources Filled

  1. Wikidata item Q3332124: mecamylamine - identity and sense of the item
  2. Wikipedia: Mecamylamine - general description of the item

Open questions

  • Does an existing Vercy world model already own mecamylamine, and does the registry intend the unqualified name to denote a racemate or a stereochemically unspecified parent substance?
  • Which authoritative structural references resolve the identifiers and relationships of the free base, hydrochloride and named stereoisomers?
  • Which primary experiments establish receptor-subtype potency, blocking mechanism and limits on selectivity claims under comparable conditions?
  • Which validated analytical methods, impurity limits and stability studies apply to bulk mecamylamine and commonly used research solutions?
  • Which medicinal products, indications and jurisdiction-specific restrictions are current, and which experimental uses remain unsupported by clinical evidence?

Machine files

Provenance

thing registry research (pass 2) · unreviewed

Built from: models/things/publications/thing-q3332124/spec.json